HomeCompareDCRE vs JNJ

DCRE vs JNJ: Dividend Comparison 2026

DCRE yields 4.80% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DCRE wins by $7.4K in total portfolio value
10 years
DCRE
DCRE
● Live price
4.80%
Share price
$51.96
Annual div
$2.49
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.4K
Annual income
$652.56
Full DCRE calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — DCRE vs JNJ

📍 DCRE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDCREJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DCRE + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DCRE pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DCRE
Annual income on $10K today (after 15% tax)
$407.95/yr
After 10yr DRIP, annual income (after tax)
$554.68/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $148.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DCRE + JNJ for your $10,000?

DCRE: 50%JNJ: 50%
100% JNJ50/50100% DCRE
Portfolio after 10yr
$23.7K
Annual income
$740.17/yr
Blended yield
3.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

DCRE
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DCRE buys
0
JNJ buys
0
No recent congressional trades found for DCRE or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDCREJNJ
Forward yield4.80%3.36%
Annual dividend / share$2.49$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$27.4K$20.0K
Annual income after 10y$652.56$827.78
Total dividends collected$5.7K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DCRE vs JNJ ($10,000, DRIP)

YearDCRE PortfolioDCRE Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,180$479.94$10,676$355.77+$504.00DCRE
2$12,464$501.47$11,407$389.39+$1.1KDCRE
3$13,859$522.49$12,198$426.53+$1.7KDCRE
4$15,372$542.96$13,056$467.62+$2.3KDCRE
5$17,011$562.84$13,987$513.12+$3.0KDCRE
6$18,784$582.10$14,998$563.56+$3.8KDCRE
7$20,699$600.72$16,098$619.52+$4.6KDCRE
8$22,767$618.67$17,295$681.69+$5.5KDCRE
9$24,997$635.95$18,599$750.82+$6.4KDCRE
10$27,399$652.56$20,022$827.78+$7.4KDCRE

DCRE vs JNJ: Complete Analysis 2026

DCREStock

DCRE offers targeted exposure to commercial real estate. The portfolio holds investment grade commercial mortgage-backed securities of any maturity or duration, including agency and non-agency CMBS, commercial real estate CLOs, and related derivatives (e.g., credit default swaps). The fund may also invest in US government-backed securities, other fixed income securities, and cash equivalents, as well as open- and closed-end investment companies and ETFs. The portfolio is managed using a controlled risk approach which involves the advisers view of potential relative performance and liquidity conditions of various market sectors, security selection within sectors, risk/reward, the shape of the yield curve, interest rate fluctuations, and current fiscal policy. The adviser intends to have a dollar-weighted average portfolio duration of three years or less. The fund may use derivatives for hedging purposes. Before February 1, 2024, the fund traded under the ticker DCMB.

Full DCRE Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this DCRE vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DCRE vs SCHDDCRE vs JEPIDCRE vs ODCRE vs KODCRE vs MAINDCRE vs ABBVDCRE vs MRKDCRE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.